| Literature DB >> 32256637 |
Fred A Ashu1,2, Jean Na-Iya3, Brice E N Wamba1, Justin Kamga3, Paul Nayim1, Bathélémy Ngameni4, Veronique P Beng2, Bonaventure T Ngadjui3, Victor Kuete1.
Abstract
Acacia polyacantha is a medicinal plant traditionally used to treat livestock diseases and gastrointestinal infections; our study was undertaken to evaluate the antistaphylococcal activities of the methanolic leaf, bark, and root extracts, fractions, and compounds from Acacia polyacantha against a panel of 14 multidrug-resistant Staphylococcus bacterial strains overexpressing efflux pumps. The study was also extended to investigate two possible modes of action, that is, influence on bacterial growth kinetics and influence on proton-ATPase pumps, of the most active compound against a reference strain. Materials and Methods. The crude extracts after extraction were subjected to column chromatography. Antibacterial assays of extracts, fractions, and compounds alone and in the presence of efflux pump inhibitors were carried out using the broth microdilution method and the study of two mechanisms of action achieved by standard methods with the most active compound. Results. The phytochemical study of Acacia polyacantha leaves leads to the isolation of stigmasterol (1), β-amyrin (2), 3-O-methyl-D-chiro-inositol (3), epicatechin (4), quercetin-3-O-galactoside (5), 3-O-[β-D-xylopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid (6), 3-O-[β-galactopyranosyl-(1⟶ 4)-β-D-galactopyranosyl]-oleanolic acid (7) and that of leaves lead to the isolation of lupeol (8) 2,3-dihydroxypropyltetracosanoate (9), and methyl-gallate (10). Leaf, root, and bark extracts inhibited 92.85% (13/14), 92.85% (13/14), and 71.43 % (10/14) of the tested bacteria strains, respectively, with minimum inhibitory concentration (MIC) varying between 16 and 1024 μg/mL. Fractions exhibited better activities compared to those of their extracts of origin, as their MICs ranged from 16 to 512 μg/mL, with fractions from leaves being more active than those obtained from barks. Compounds had varying activities; MICs varied from 16 to 512 μg/mL with compound 4 presenting the best activity as MICs ≤100 μg/mL were obtained against 11 of the tested bacteria. The activities of extracts, fractions, and compounds were improved in the presence of carbonyl cyanide m-chlorophenylhydrazone (CCCP) as an efflux pump inhibitor to as much as >128 folds. Meanwhile, in the presence of chlorpromazine as an efflux pump inhibitor, only the activity of compound 10 was improved on 10 of the tested bacteria strains. Compound 4 prolonged the lag phase of the growth kinetic in a concentration-dependent manner and equally inhibited the proton-ATPase pumps of the tested bacteria strains. Conclusion. The present study demonstrates the antistaphylococcal potential of Acacia polyacantha and its constituents to combat bacterial infections alone or in combination with efflux pump inhibitors.Entities:
Year: 2020 PMID: 32256637 PMCID: PMC7102469 DOI: 10.1155/2020/2654247
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structures of compound isolated leaves and barks of A. polyacantha. 1: stigmasterol, 2: β-amyrin, 3: 3-(O)-methyl-D-chiro-inositol, 4: Epicatechin, 5: Quercetin-3-(O)-galactoside, 6: 3-(O)-[β-D-xylopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid, 7: 3-(O)-[β-D-galactopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid, 8: Lupeol, 9: 2,3-dihydroxylpropyltétracosanoate, 10: methyl gallate.
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) in μg/mL of crude extracts from Acacia polyacantha and ciprofloxacin against S. aureus strain.
| Tested samples, MICs in | ||||
|---|---|---|---|---|
| Bacteria | Stem bark extract | Leaf extract | Root extract | Ciprofloxacin |
|
| 256(-) | 512(-) | 1024(-) | 8(-) |
|
| 256(-) | 128(-) | 128(-) | 2(-) |
|
| 256(-) | 128(-) | 1024(-) | 1 |
|
| 1024(-) | 256(-) | 1024(-) | 2 |
|
| 512(-) | 1024(-) | 1024(-) | 2(-) |
|
| 512(-) | 512(-) | 1024(-) | 2(-) |
|
| 1024(-) | 512(-) | 1024(-) | 2(16) |
|
| 1024(-) | 512(-) | 1024(-) | 2(-) |
|
| — | 512(-) | 1024(-) | 2(-) |
|
| 16(-) | 128(-) | 512(-) | ≤0.5(-) |
|
| — | 64(-) | ≤0.5(-) | |
|
| 32(-) | 16(-) | 512(-) | ≤0.5(8) |
|
| — | 512(-) | 64(-) | ≤0.5(8) |
|
| — | 128(-) | — | ≤0.5(-) |
(-): ≥1024 μg/mL; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; MRSA: methicillin-resistant Staphylococcus aureus; SA: Staphylococcus aureus; MSSA: methicillin susceptible Staphylococcus aureus.
MICs (μg/mL) of stem bark and leaf fractions.
| Bacteria | Fractions, MICs, and MBCs (in parentheses) in | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| 64(-) | — | 16(-) | 512(-) | 256(-) | 64(-) | — | 512(-) | 256(-) | — | 512(-) |
|
| 32(-) | 512(-) | 64(-) | 512(-) | 256(-) | 64(-) | — | 256(-) | — | — | 128(-) |
|
| 64(-) | — | 64(-) | 512(-) | 512(-) | 128(-) | — | — | — | — | — |
|
| 64(-) | 256(-) | — | — | 128(-) | 64(-) | — | — | — | — | 512(-) |
|
| 64(-) | — | 32(-) | — | 256(-) | 64(-) | ≤4(-) | 512(-) | — | — | 512(-) |
|
| 128(-) | — | 64(-) | 128(-) | 128(-) | 128(-) | — | 256(-) | — | — | 512(-) |
|
| 32(-) | 512(-) | — | 512(-) | 128(-) | 64(-) | — | 512(-) | — | — | 32(-) |
|
| 64(-) | 256(-) | 64(-) | — | 256(-) | 32(-) | — | 512(-) | — | — | 512(-) |
|
| 64(-) | 256(-) | — | — | 512(-) | 64(-) | — | 512(-) | — | — | 128(-) |
|
| — | — | 64(-) | — | 512(-) | — | — | 512(-) | — | — | 128(-) |
|
| — | 16(-) | — | — | 256(-) | 512(-) | — | 256(-) | — | — | — |
|
| 512(-) | — | 128(-) | — | 128(-) | 256(-) | — | 256(-) | 16(-) | — | 16(-) |
|
| 64(-) | 128(-) | — | 256(-) | 512(-) | 64(-) | — | — | — | — | — |
|
| 64(-) | 512(-) | 256(-) | — | 512(-) | 256(-) | — | — | — | 256 | — |
(-): ≥512 μg/ml; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; MRSA: methicillin-resistant Staphylococcus aureus; SA: Staphylococcus aureus; MSSA: methicillin susceptible Staphylococcus aureus; F: fraction from leaves; F′: fractions from barks; fractions F5–F7, F9, F1′–F5′, F7′, F8′, and F13′ were not active.
MICs (μg/mL) of isolated compounds from leaves and stem barks of Acacia polyacantha.
| Compounds, MICs, and MBCs (in parentheses) in | ||||||||
|---|---|---|---|---|---|---|---|---|
| Bacteria |
|
|
|
|
|
|
|
|
|
| 512 (-) | 128 (-) | 32 | — | — | — | — | 512 (-) |
|
| 256 (-) | 32 (-) | 16 | — | — | 256 (-) | — | 256 (-) |
|
| — | 64 (-) | 64 | — | — | — | — | 512 (-) |
|
| — | 64 (-) | 32 (512) | — | — | 128 (-) | — | 256 (-) |
|
| 512 (-) | 128 (-) | 128 | — | 256 (-) | 256 (-) | — | 512 (-) |
|
| 256 (-) | 64 (-) | 32 (512) | — | — | 64 (-) | — | 512 (-) |
|
| 256 (-) | 64 (-) | 16 (512) | — | — | 256 (-) | — | 256 (-) |
|
| 256 (-) | 128 (-) | 32 (256) | — | — | 512 | — | 512 (-) |
|
| 512 (-) | 32 (-) | 16 | — | — | 256 (-) | — | 256 (-) |
|
| 128 (-) | 128 (-) | 64 | 512 (-) | — | 256 (-) | 512 (-) | 32 (-) |
|
| 512 (-) | 64 (-) | — | — | — | — | — | 64 (-) |
|
| — | 64 (-) | 64 | 512 (-) | — | 512 (-) | 512 (-) | 16 (-) |
|
| — | 128 (-) | 16 | — | — | 128 (-) | — | 512 (-) |
|
| 256 (-) | 512 (-) | — | — | — | — | — | 128 (-) |
(-): ≥512 μg/mL; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; MRSA: methicillin-resistant Staphylococcus aureus; SA: Staphylococcus aureus; MSSA: methicillin susceptible Staphylococcus aureus; 2: β-amyrin; 1: stigmasterol; 3: 3-O-méthyl-D-chiro-inositol; 4: epicatechin; 5: quercetin-3-O-glucoside; 6: 3-O-[β-D-xylopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid; 7: 3-O-[β galactopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid; 8: Lupeol; 9: 2,3-dihydroxypropyltetracosanoate; 10: methyl gallate. Compounds 1 and 8 were not active on all tested bacteria.
MICs (μg/mL) of tested samples in the presence of carbonyl cyanide (m)-chlorophenylhydrazone (CCCP).
| Bacteria | Tested samples, MIC ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bark crude extracts | Root extract | Leaf extract | Bark (EAF) | F8 | 3 | 4 | 7 | 10 | Ciprofloxacin | |
|
| 32 ( | 64 ( | 64 ( | 64 ( | 128 ( | 16 ( | 8 ( | 128 (≥ | 32 ( | ≤0.5 (≥1) |
|
| ≤4 (≥ | ≤4 ( | ≤4 (≥ | 64 ( | ≤2 (≥ | ≤2 ( | ≤2 ( | ≤4 (≥ | 8 ( | ≤0.5 ( |
|
| 64 ( | 8 ( | 32 ( | ≤4 (≥ | 128 ( | ≤2 ( | 16 ( | 256 (≥ | 32 ( | ≤0.5 ( |
|
| 16 ( | 256 ( | ≤4 ( | 256 ( | 64 ( | ≤2 ( | 32 (1) | 8 ( | 16 ( | ≤0.5 ( |
|
| 128 ( | 512 ( | 512 ( | 512 (≥ | 64 ( | ≤2 ( | ≤2 ( | 64 ( | 64 ( | ≤0.5 ( |
|
| 16 ( | 512 ( | 128 | 16 ( | 64 ( | 4 ( | 2 ( | 16 ( | 16 ( | ≤0.5 ( |
|
| 512 ( | 512 ( | 512 (1) | 512 (1) | 64 ( | 16 ( | 8 ( | 128 ( | 64 ( | ≤0.5 ( |
|
| 512 ( | 512 ( | 512 (1) | - (-) | 8 ( | 32 ( | 8 ( | 8 ( | 8 ( | ≤0.5 ( |
|
| 32 (≥ | 128 ( | 256 ( | 8 ( | 32 ( | 16 ( | 8 ( | 64 ( | 8 ( | ≤0.5 ( |
|
| 16 ( | 64 | 128 (1) | 128 (1) | 256 ( | ≤2 ( | ≤2 ( | 32 ( | 16 ( | ≤0.5 (≥1) |
|
| 512 (≥ | ≤4 (≥ | 512 (≥ | 64 (≥ | 128 ( | 16 ( | - (≤1) | 64 (≥ | 16 ( | ≤0.5 (≥1) |
|
| 16 ( | 8 ( | ≤4 (≥ | ≤4 (≥ | 64 ( | ≤2 ( | 16 ( | 512 (1) | ≤2 (≥ | ≤0.5 (≥1) |
|
| - (1) | 512 (0.125) | 64 ( | ≤4 (≥ | 128 ( | 16 ( | - (-) | 32 ( | 32 ( | ≤0.5 (≥1) |
|
| 128 (≥ | 128 (≥ | 64 ( | 256 (≥ | 32 ( | 32 ( | 32 ( | 128 (≥ | 128 (1) | ≤0.5 (≥1) |
(-): ≥1024 μg/mL; CCCP: carbonyl cyanide m-chlorophenylhydrazone; AAF: activity amelioration factor; in bold are AAF ≥2; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; MRSA: methicillin-resistant Staphylococcus aureus; SA: Staphylococcus aureus; MSSA: methicillin susceptible Staphylococcus aureus; 3: 3-O-méthyl-D-chiro-inositol; 4: epicatechin; 7: 3-O-[β galactopyranosyl-(1 ⟶ 4)-β-D-galactopyranosyl]-oleanolic acid; 10: methyl gallate.
MICs (μg/mL) of tested samples in the presence of chlorpromazine (CPZ).
| Bacteria | Tested samples, MIC ( | ||||
|---|---|---|---|---|---|
| Root extract | 3 | 7 | 10 | Ciprofloxacin | |
|
| - (≤1) | - (≤0.12) | - (nd) | 64 ( | ≤0.5 (≥1) |
|
| - (≤0.12) | - (≤0.03) | - (≤0.25) | 64 ( | ≤0.5 ( |
|
| 256 ( | ≤2 | - (nd) | 64 ( | ≥0.5 ( |
|
| - (≤1) | - (≤0.06) | - (≤0.12) | 32 ( | 1 ( |
|
| - (≤1) | ≤2 ( | 256 (1) | 128 ( | 2 (1) |
|
| - (≤1) | - (≤0.06) | - (≤0.06) | 64 ( | ≤0.5 ( |
|
| - (nd) | 64 (1) | - (≤0.25) | 128 ( | ≤0.5 ( |
|
| - (nd) | - (≤0.12) | - (≤0.5) | 64 ( | 2 (1) |
|
| - (≤1) | - (≤0.03) | - (≤0.25) | 64 ( | 0.5 ( |
|
| - (≤0.5) | - (≤0.12) | - (≤0.25) | 64 (0.5) | ≤0.5 (≥1) |
|
| - (≤0.06) | - (≤0.06) | - (nd) | 128 (0.5) | ≤0.5 (≥1) |
|
| - (≤0.5) | - (≤0.06) | - (≤0.5) | 64 (0.25) | ≤0.5 (≥1) |
|
| - (≤0.06) | - (≤0.12) | - (≤0.12) | 128 ( | ≤0.5 (≥1) |
|
| - (nd) | - (≤0.5) | - (nd) | 128 (1) | ≤0.5 (≥1) |
(-): ≥1024 μg/mL; CCCP: carbonyl cyanide m-chlorophenylhydrazone; AAF: activity amelioration factor; in bold are AAF ≥2; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration; MRSA: methicillin-resistant Staphylococcus aureus; SA: Staphylococcus aureus; MSSA: methicillin susceptible Staphylococcus aureus; bark and leaf extracts as well as fraction 8 and compound 4 were tested but were not active; nd: not determined.
Figure 2Effects of compound 4 on the growth kinetics of ATCC25923.
Figure 3Effects of compound 4 on the proton-ATPase pumps.